3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Trastuzumab
2
Quality of Life
2
Fluorodeoxyglucose F18
2
tislelizumab
1
tipifarnib
1
surufatinib
1
regorafenib
1
milademetan
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
entinostat
1
copper dotatate CU-64
1
Surveys and Questionnaires
1
Ritonavir
1
Radiotherapy
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Patient Reported Outcome Measures
1
PM 01183
1
Oxaliplatin
1
N-Ac-CHAVC-NH2
1
Molecular Diagnostic Techniques
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Clinical Trials, Phase II as Topic
×
Endocrine
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled